Overview

25-Gauge Vitrectomy With Ranibizumab or Triamcinolone Acetonide on Proliferative Diabetic Retinopathy in China

Status:
Unknown status
Trial end date:
2017-05-01
Target enrollment:
0
Participant gender:
All
Summary
Proliferative diabetic retinopathy(PDR) is the leading cause of visual loss in diabetic patients. Operation is an efficient method to treat PDR. Anti-vascular endothelial growth factor (anti-VEGF) can be used as an adjuvant therapy which can make operation more easy.
Phase:
Phase 2/Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
JUNYAN ZHANG
Collaborator:
The First People's Hospital of Xuzhou
Treatments:
Ranibizumab
Triamcinolone
Triamcinolone Acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide
Criteria
Inclusion Criteria:

- Type II diabetes mellitus with Diabetic Retinopathy

- Vitreous hemorrhage/Proliferation of retinal/Tractional detachment of retina

- Fasting blood-glucose no more than 8mmol/ml

Exclusion Criteria:

- Subjects who have operation on vitreous before

- Accompany with other ophthalmology diseases except cataract

- History of vitrectomy surgery in the study eye

- Previous subfoveal focal laser photocoagulation in the study eye

- Previous participation in a clinical trial (for either eye)

- Previous subfoveal focal laser photocoagulation in the study eye

- Other diseases cannot afford Vitrectomy